美國液體栓塞劑市場規模、佔有率和趨勢分析報告：按產品、應用、最終用途和細分市場預測，2025 年至 2033 年

美國液態栓塞劑市場摘要

美國液體栓塞劑市場規模預計在 2024 年達到 6,697 萬美元，預計到 2033 年將達到 1.4685 億美元，2025 年至 2033 年的複合年成長率為 9.26%。推動這一成長的因素包括技術進步、血管疾病患病率的上升、對微創手術的偏好日益成長、栓塞劑材料的進步以及應用領域的不斷擴大。

神經血管疾病和周邊血管疾病（例如動脈瘤、動靜脈畸形 (AVM) 和富血管腫瘤）的發生率日益上升，推動了對有效栓塞解決方案的需求，並刺激了市場擴張。這些疾病通常需要微創手術來阻斷異常血管、防止破裂或減少腫瘤的血液供應。液體栓塞劑尤其適合這些治療，因為它們能夠精準靶向複雜的血管結構，有效消除血管，同時最大限度地減少附帶損害。

隨著對這些疾病的認知不斷提高和診斷技術的進步，越來越多的患者被早期診斷並需要栓塞治療。此外，氰基丙烯酸正丁酯 (n-BCA) 和乙烯 - 乙烯醇共聚物 (EVOH) 等栓塞材料的進步提高了這些手術的安全性和有效性，使其成為對臨床醫生更具吸引力的選擇。血管內手術的日益普及進一步推動了液體栓塞劑的使用。因此，神經血管和周邊血管病例的激增、技術進步以及臨床接受度的提高正在推動市場擴張。例如，美敦力公司於 2025 年 7 月宣布招募周邊 Onyx 液體栓塞 (PELE) 臨床試驗的第一位患者。該試驗旨在評估 Onyx 液體栓塞系統 (LES) 對周邊血管動脈出血進行栓塞的安全性和有效性。

液體栓塞劑廣泛用於治療各種疾病，包括動靜脈畸形 (AVM)、富血管腫瘤、周邊出血和其他血管異常。中風、癌症和創傷的發生率上升，推動了美國對有效栓塞療法的需求不斷成長。例如，根據巴羅神經學研究所的數據，約有 30 萬美國人患有腦部或脊髓動靜脈畸形（神經動靜脈畸形），但只有約 12% 的患者會出現症狀。

在美國營運美國FDA核准產品的主要企業包括Medtronic、Serenobus（強生）、波士頓科學公司、Terumo Corporation、Sirtex（黑天鵝血管）等。此外，氰基丙烯酸酯、非黏附性材料和乙烯 - 乙烯醇共聚物等先進栓塞材料的採用提高了治療效果和安全性，刺激了市場擴張。

門診手術的趨勢也促進了市場的成長，門診手術中心擴大採用栓塞治療，因為它具有成本效益和患者便利性。根據 2022 年 4 月發表在《介入性神經放射學》上的一篇研究論文，美國醫院正在利用液體栓塞系統 (LES)，例如氰基丙烯酸正丁酯 (n-BCA) 和乙烯 - 乙烯醇共聚物 (EVOH)，對腦動靜脈畸形 (bAVM) 進行栓塞，以促進術前重組。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章美國液態栓塞劑市場變數、趨勢與範圍

• 市場體系展望
  • 補貼市場展望
• 市場動態
  • 市場促進因素分析
  • 市場限制因素分析
  • 市場機會分析
  • 市場問題分析
• 美國液態栓塞劑市場分析工具
  • 產業分析-波特五力分析
  • PESTEL分析

第4章美國液體栓塞劑市場：按產品分類的估計和趨勢分析

• 細分儀表板
• 美國液態栓塞劑市場產品波動分析
• 2021-2033 年美國液態栓塞劑市場規模及產品趨勢分析
• 乙烯 - 乙烯醇共聚物（EVOH）
• 氰基丙烯酸酯
  • N-BCA
  • N-HCA
• 其他

第5章美國液體栓塞劑市場：應用預測與趨勢分析

• 細分儀表板
• 美國液態栓塞劑市場應用波動分析
• 美國液態栓塞劑市場規模及應用趨勢分析（2021-2033）
• 動靜脈畸形（AVM）
• 富血管腫瘤
• 周邊血管出血
• 其他

第6章：美國液體栓塞劑市場：按最終用途的估計和趨勢分析

• 細分儀表板
• 美國液態栓塞劑市場最終用途波動分析
• 美國液態栓塞劑市場規模及趨勢分析（依最終用途），2021-2033 年
• 醫院
• 專科診所
• 門診手術中心
• 其他

第7章 競爭態勢

• 市場參與企業分類
• 主要企業簡介
  • Medtronic
  • Terumo
  • Boston Scientific Corporation
  • Johnson &Johnson
  • Sirtex（BlackSwan Vascular, Inc.）
  • Others
• 2024年公司市場佔有率分析
• 其他主要市場公司名單

U.S. Liquid Embolic Agent Market Summary

The U.S. liquid embolic agent market size was estimated at USD 66.97 million in 2024 and is projected to reach USD 146.85 million by 2033, growing at a CAGR of 9.26% from 2025 to 2033. This growth is driven by technological advancements, increasing prevalence of vascular disorders, rising preference for minimally invasive procedures, advancements in embolic agent materials, and expanding application areas.

The increasing incidence of neurovascular and peripheral vascular conditions such as aneurysms, arteriovenous malformations (AVMs), and hypervascular tumors has increased demand for effective embolization solutions, fueling market expansion. These conditions often require minimally invasive procedures to block abnormal blood vessels, prevent rupture, or reduce tumor blood supply. Liquid embolic agents are particularly well-suited for these treatments because they precisely target complex vascular structures, providing effective devascularization with minimal collateral damage.

As awareness of these conditions increases and diagnostic techniques improve, more patients are diagnosed early and require embolization therapy. In addition, advancements in embolic materials, such as n-butyl cyanoacrylate (n-BCA) and ethylene vinyl alcohol copolymer (EVOH), have enhanced the safety and efficacy of these procedures, making them more attractive options for clinicians. The expanding adoption of endovascular techniques further boosts the utilization of liquid embolic agents. Consequently, this surge in neurovascular and peripheral vascular condition cases, technological progress, and growing clinical acceptance fuel market expansion. For instance, in July 2025, Medtronic announced the enrollment of the first patient in the Peripheral Onyx Liquid Embolic (PELE) clinical trial. This study aims to assess the safety and efficacy of the Onyx Liquid Embolic System (LES) for the embolization of arterial hemorrhages in the peripheral vasculature.

Liquid embolic agents are widely used in the treatment of various conditions such as arteriovenous malformations (AVMs), hypervascular tumors, peripheral hemorrhages, and other vascular anomalies. The growing incidence of stroke, cancer, and traumatic injuries has increased demand for effective embolization therapies in the country. For instance, according to Barrow Neurological Institute, approximately 300,000 Americans are affected by AVMs of the brain and spinal cord (neurological AVMs), but only around 12 percent of those affected experience symptoms.

Some of the key players operating in the U.S. and having U.S. FDA-approved products include Medtronic, CERENOVUS (Johnson & Johnson), Boston Scientific Corporation, Terumo, and Sirtex (BlackSwan Vascular, Inc.). Furthermore, the adoption of advanced embolic materials, including cyanoacrylate-based, non-adhesive, and ethylene vinyl alcohol copolymer agents, has improved procedural outcomes and safety profiles, fueling market expansion.

The trend toward outpatient procedures is also contributing to market growth, with ambulatory surgical centers increasingly adopting embolization techniques due to their cost-effectiveness and patient convenience. According to a research article published in the Interventional Neuroradiology journal in April 2022, liquid embolic systems (LESs) such as n-butyl cyanoacrylate (n-BCA) and ethylene vinyl alcohol copolymer (EVOH) are utilized for the embolization of brain arteriovenous malformations (bAVMs) to facilitate presurgical devascularization in U.S. hospitals.

U.S. Liquid Embolic Agent Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. liquid embolic agent market report based on product, application, and end use:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Ethylene Vinyl Alcohol Copolymer (EVOH)
• Cyanoacrylates
  • N-BCA
  • N-HCA
• Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Arteriovenous Malformations (AVM)
• Hypervascular Tumors
• Peripheral Vasculature Hemorrhage
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Specialty Clinics
• Ambulatory Surgery Centers
• Other End Use

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. End Use
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
  • 1.5.5. Information Analysis
  • 1.5.6. Data Analysis Models
• 1.6. Market Formulation & Data Visualization
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
• 1.8. List of Secondary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Liquid Embolic Agent Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing incidence of conditions such as arteriovenous malformations (AVMs), aneurysms, and hemorrhages necessitates embolization procedures
    • 3.2.1.2. Advancements in embolization technologies
    • 3.2.1.3. Increasing adoption in oncology treatments
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High cost of materials and procedures
    • 3.2.2.2. Strict regulatory approvals and compliance
  • 3.2.3. Market Opportunities Analysis
    • 3.2.3.1. Emerging applications
  • 3.2.4. Market Challenges Analysis
• 3.3. U.S. Liquid Embolic Agent Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political & Legal Landscape
    • 3.3.2.2. Economic and Social Landscape
    • 3.3.2.3. Technological landscape

Chapter 4. U.S. Liquid Embolic Agent Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. U.S. Liquid Embolic Agent Market Product Movement Analysis
• 4.3. U.S. Liquid Embolic Agent Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 4.4. Ethylene Vinyl Alcohol Copolymer (EVOH)
  • 4.4.1. Ethylene Vinyl Alcohol Copolymer (EVOH) U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Cyanoacrylates
  • 4.5.1. Cyanoacrylates U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.2. N-BCA
    • 4.5.2.1. N-BCA U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.3. N-HCA
    • 4.5.3.1. N-HCA U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Others
  • 4.6.1. Others U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Liquid Embolic Agent Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. U.S. Liquid Embolic Agent Market Application Movement Analysis
• 5.3. U.S. Liquid Embolic Agent Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 5.4. Arteriovenous Malformations (AVM)
  • 5.4.1. Arteriovenous Malformations (AVM) U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Hypervascular Tumors
  • 5.5.1. Hypervascular Tumors U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Peripheral Vasculature Hemorrhage
  • 5.6.1. Peripheral Vasculature Hemorrhage U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Others
  • 5.7.1. Others U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Liquid Embolic Agent Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. U.S. Liquid Embolic Agent Market End Use Movement Analysis
• 6.3. U.S. Liquid Embolic Agent Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 6.4. Hospitals
  • 6.4.1. Hospitals U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Specialty Clinics
  • 6.5.1. Specialty Clinics U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Ambulatory Surgery Centers
  • 6.6.1. Ambulatory Surgery Centers U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Other End Use
  • 6.7.1. Other End Use U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Market Participant Categorization
• 7.2. Key Company Profiles
  • 7.2.1. Medtronic
    • 7.2.1.1. Company Overview
    • 7.2.1.2. Financial Performance
    • 7.2.1.3. Product Benchmarking
    • 7.2.1.4. Strategic Initiatives
  • 7.2.2. Terumo
    • 7.2.2.1. Company Overview
    • 7.2.2.2. Financial Performance
    • 7.2.2.3. Product Benchmarking
    • 7.2.2.4. Strategic Initiatives
  • 7.2.3. Boston Scientific Corporation
    • 7.2.3.1. Company Overview
    • 7.2.3.2. Financial Performance
    • 7.2.3.3. Product Benchmarking
    • 7.2.3.4. Strategic Initiatives
  • 7.2.4. Johnson & Johnson
    • 7.2.4.1. Company Overview
    • 7.2.4.2. Financial Performance
    • 7.2.4.3. Product Benchmarking
    • 7.2.4.4. Strategic Initiatives
  • 7.2.5. Sirtex (BlackSwan Vascular, Inc.)
    • 7.2.5.1. Company Overview
    • 7.2.5.2. Financial Performance
    • 7.2.5.3. Product Benchmarking
    • 7.2.5.4. Strategic Initiatives
  • 7.2.6. Others
    • 7.2.6.1. Company Overview
    • 7.2.6.2. Financial Performance
    • 7.2.6.3. Product Benchmarking
    • 7.2.6.4. Strategic Initiatives
• 7.3. Company Market Share Analysis, 2024
• 7.4. List of Other Key Market Players

List of Tables

• Table 1. List of Secondary Sources
• Table 2. List of Abbreviations
• Table 3. U.S. Liquid Embolic Agent Market, by Product, 2021 - 2033 (USD Million)
• Table 4. U.S. Liquid Embolic Agent Market, by Application, 2021 - 2033 (USD Million)
• Table 5. U.S. Liquid Embolic Agent Market, by End Use, 2021 - 2033 (USD Million)
• Table 6. Participant's Overview
• Table 7. Financial Performance
• Table 8. Product Benchmarking
• Table 9. Strategic Initiatives

List of Figures

• Fig. 1 Information Procurement
• Fig. 2 Primary Research Pattern
• Fig. 3 Market Research Approaches
• Fig. 4 Value Chain-Based Sizing & Forecasting
• Fig. 5 Market Formulation & Validation
• Fig. 6 U.S. Liquid Embolic Agent Market, Market Segmentation
• Fig. 7 Market Driver Analysis (Current & Future Impact)
• Fig. 8 Market Restraint Analysis (Current & Future Impact)
• Fig. 9 Market Opportunity Analysis (Current & Future Impact)
• Fig. 10 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
• Fig. 11 Porter's Five Forces Analysis
• Fig. 12 Regional Marketplace: Key Takeaways
• Fig. 13 U.S. Liquid Embolic Agent Market, for Product, 2021 - 2033 (USD Million)
• Fig. 14 U.S. Liquid Embolic Agent Market, for Ethylene Vinyl Alcohol Copolymer (EVOH), 2021 - 2033 (USD Million)
• Fig. 15 U.S. Liquid Embolic Agent Market, for Cyanoacrylates, 2021 - 2033 (USD Million)
• Fig. 16 U.S. Liquid Embolic Agent Market, for N-BCA, 2021 - 2033 (USD Million)
• Fig. 17 U.S. Liquid Embolic Agent Market, for N-HCA, 2021 - 2033 (USD Million)
• Fig. 18 U.S. Liquid Embolic Agent Market, for Others, 2021 - 2033 (USD Million)
• Fig. 19 U.S. Liquid Embolic Agent Market, for Arteriovenous Malformations (AVM), 2021 - 2033 (USD Million)
• Fig. 20 U.S. Liquid Embolic Agent Market, for Hypervascular Tumors, 2021 - 2033 (USD Million)
• Fig. 21 U.S. Liquid Embolic Agent Market, for Peripheral Vasculature Hemorrhage, 2021 - 2033 (USD Million)
• Fig. 22 U.S. Liquid Embolic Agent Market, for Others, 2021 - 2033 (USD Million)
• Fig. 23 U.S. Liquid Embolic Agent Market, for End Use, 2021 - 2033 (USD Million)
• Fig. 24 U.S. Liquid Embolic Agent Market, for Hospitals, 2021 - 2033 (USD Million)
• Fig. 25 U.S. Liquid Embolic Agent Market, for Specialty Clinics, 2021 - 2033 (USD Million)
• Fig. 26 U.S. Liquid Embolic Agent Market, for Ambulatory Surgery Centers, 2021 - 2033 (USD Million)
• Fig. 27 U.S. Liquid Embolic Agent Market, for Other End Use, 2021 - 2033 (USD Million)